BTX vs DBVT Comparison

BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.